Corcept Therapeutics
CORT
55 hedge funds and large institutions have $97.5M invested in Corcept Therapeutics in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $102M → $97.5M (-$4.33M)
11% less funds holding
Funds holding: 62 → 55 (-7)
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ISL
Ingalls & Snyder LLC
New York
|
+$1.21M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$156K |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$146K |
| 4 |
State Street
Boston,
Massachusetts
|
+$130K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$101K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$457K |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$271K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$213K |
| 4 |
CIA
Capital Impact Advisors
Boston,
Massachusetts
|
-$158K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$147K |
CORT Hedge Fund Activity: Q3 2014 in Review
55 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2014, worth a combined $97.5M — down 4.3% from $102M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CORT and 3 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 13 added.
The largest buyer was Ingalls & Snyder LLC, adding an estimated $1.21M. The largest seller was Goldman Sachs, exiting entirely with an estimated $457K sold.
- 55 institutional investors held Corcept Therapeutics (CORT) as of Q3 2014, down from 62 in Q2 2014.
- Funds reported $97.5M of Corcept Therapeutics stock for Q3 2014, down 4.3% quarter-over-quarter.
- 3 funds opened new Corcept Therapeutics positions in Q3 2014 and 10 closed out, a net change of -7 holders.
- The largest Corcept Therapeutics buyer in Q3 2014 was Ingalls & Snyder LLC, an estimated $1.21M added.
- The largest Corcept Therapeutics seller in Q3 2014 was Goldman Sachs, an estimated $457K sold.
Based on aggregated 13F filings for Q3 2014.